Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy
VIEWPOINTS

PharmaShots Interview: Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy

In an interview with PharmaShots, Toby Ferguson, Vice President & Head of the Neuromuscular Development Unit at Biogen shared his views on new data on Spinraza and improves clinical outcomes for the treatment of SMA patients Shots: The first patient has been treated in the P-IIIb (ASCEND) study evaluating the higher dose of nusinersen in 135 children, teens & adults with…
May 10, 2022

Read more

Exclusive_Todd Zavodnick_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Todd Zavodnick of Dermavant Shares Insight on the Appointment of Nancy Beesley with 25+ Years of Experience

In an interview with PharmaShots, Todd Zavodnick, CEO at Dermavant, shared his views on the addition of Nancy Beesley to its Board of Directors. She brings over 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseases Shots: The addition of Nancy as a board member…
May 9, 2022

Read more

PharmaShots Interview X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies
VIEWPOINTS

PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies

In an interview with PharmaShots, Paula Ragan, Ph.D., CEO, and President at X4 Pharmaceuticals shared her views on the data of Mavorixafor which showed increased immune cell levels regardless of patients having a CXCR4 mutation to treat multiple immunodeficiencies, presented at ASH 2021 Shots: The ongoing long-term extension arm of the P-II trial evaluates Mavorixafor (CXCR4 antagonist) in patients with WHIM syndrome. The therapy continues…
May 3, 2022

Read more

PharmaShots Interview Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myeloma The P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…
May 2, 2022

Read more

PharmaShots Interview Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs
VIEWPOINTS

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on Proclaim XR Spinal Cord Stimulation System for the Treatment of Chronic Intractable Pain of Trunk and Limbs

In an interview with PharmaShots, Dr. Allen Burton, Medical Director of Abbott’s Neuromodulation Business shared his views on the US FDA approval for expanded MRI compatibility of Its Proclaim XR SCS Device Shots: The US FDA has approved new expanded MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads. The Proclaim XR SCS System is an…
April 11, 2022

Read more

PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more

Exclusive_Jeremiah Robison_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the US FDA’s clearance of Neural Sleeve for patients with cerebral palsy, MS, stroke, and other disorders Cionic’s Neural Sleeve has received the US FDA clearance for functional electrical stimulation to assist in gait for patients with foot drop and leg muscle weakness. The lightweight…
March 30, 2022

Read more

Exclusive_John Meduri_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit. Shots: Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 2022

Read more

EXCLUSIVE

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

In an interview with PharmaShots, Moshe Safran, CEO at RSIP Vision shared his views on the new coronary module in the complete 3D reconstruction of the coronary vasculature during angiography Shots: The company reported the 3D reconstruction technology that focused on AI to generate 3D models of patient anatomy from 2D images. The purpose of the technology is to create precise,…
February 7, 2022

Read more

Viewpoints_Laura Dix
VIEWPOINTS

PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions

In an interview with PharmaShots, Laura Dix, a Managing Director in Accenture’s Life Sciences Strategy and Consulting practice shares her views on the new research & provides more useful, data-driven information to HCPs  Shots: The company unveiled new research, titled The “New” Rules of Engagement & which have increased their relevance during COVID-19 through more valuable and meaningful interactions with…
February 2, 2022

Read more

Load more